Is serum uric acid a predictive factor of response to IFN-treatment in patients with chronic hepatitis C infection?

Journal of Medical Virology

Volumn 80, Issue 4, 2008, Pages 628-631

  Pellicano, Rinaldo ^a,d   Puglisi, Giovanni ^a,b   Ciancio, Alessia ^a   Balzola, Federico ^a   Saracco, Giorgio ^a   Ciccone, Giovannino ^c   Baldi, Ileana ^c   Abate, Maria Lorena ^a   Smedile, Antonina ^a   Rizzetto, Mario ^a  

^a MOLINETTE HOSPITAL   (Italy)

^b UNIVERSITY OF CATANIA   (Italy)

^c UNIVERSITY OF TURIN   (Italy)

^d Ambulatori di Gastro Epatologia   (Italy)

Author keywords

HCV; Peginterferon; Ribavirin; Uric acid

Indexed keywords

PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; URIC ACID; VIRUS RNA;

ADULT; ARTICLE; FEMALE; GENOTYPE; HEPATITIS C; HUMAN; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PROGNOSIS; RETROSPECTIVE STUDY; SCORING SYSTEM; STATISTICAL MODEL; TREATMENT RESPONSE; URIC ACID BLOOD LEVEL; VIROLOGY; VIRUS LOAD;

ADULT; AGED; ANTIVIRAL AGENTS; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; LIVER CIRRHOSIS; LOGISTIC MODELS; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; RIBAVIRIN; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; URIC ACID; VIRAL LOAD;

HEPATITIS C VIRUS; HEPATITIS C VIRUS GENOTYPE 1;

EID: 40549111664     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.21123     Document Type: Article

References (28)

1. Avogaro A. 2006. Insuline resistance: Trigger or concomitant factor in the metabolic syndrome. Panminerva Med 48:3-12.
2. Craxì A, Cammà C, Giunta M. 1999. Definition of response to antiviral therapy in chronic hepatitis C. J Hepatol 31:166-167.
3. Davis GL, Lau JYN. 1997. Factors predicting of a beneficial response to therapy of hepatitis C. Hepatology 26:S122-S127.
4. Dumoulin FL, Wennrich U, Nischalke HD, Leifeld L, Fischer HP, Sauerbruch T, Spengler U. 2001. Intrahepatic mRNA levels of interferon gamma and tumor necrosis factor alpha and response to antiviral treatment of chronic hepatitis C. J Hum Virol 4:195-199.
5. El-Serag HB. 2002. Hepatocellular carcinoma. An epidemiologic view. J Clin Gastroenterol 35:S72-S78.
6. Fontana RJ. 2001. Uric acid nephrolithiasis associated with interferon and ribavirin treatment of hepatitis C. Dig Dis Sci 46:920-924.
7. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL, Häussinger D, Diago M, Carosi G, Dhumeaux D, Craxì A, Lin A, Hoffman J, Yu J. 2002. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347:975-982.
8. Grant RW, Meigs JB. 2005. Management of the metabolic syndrome. Panminerva Med 48:219-228.
9. Hanley JA, McNeil BJ. 1982. The meaning and the use of the area under a receiver operating characteristic (ROC) curve. Radiology 143:29-36.
10. Hooper DC, Spitsin S, Kean RB, Champion JM, Dickson GM, Chaudry I, Kopiowski H. 1998. Uric acid, a natural scavenger of peroxynitrite, in experimental allergic encephalomyelitis and multiple sclerosis. Proc Natl Acad Sci 95:675-680.
11. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, Denk H, Desmet, V, Korb G, Mac Sween RN. 1995. Histological grading and staging of chronic hepatitis. J Hepatol 22:696-699.
12. Lee SS. 2003, Review article: Indicators and predictors of response to anti-viral therapy in chronic hepatitis C. Aliment Pharmacol Ther 17:611-621.
13. Lilinfield AM, Lilinfield DE. 1980. Foundations of epidemiology. New York: Oxford University Press.
14. Lopez-Suarez A, Elvira-Gonzalez J, Bascunana-Quirell A, Rosal-Obrador J, Michan-Dona A, Escribano-Serrano J, Benitez-Rodriguez E, Grupo para el studio del riesco vascular alcala (GERVA). 2006. Serum urate levels and urinary uric acid excretion in subjects with metabolic syndrome. Med Clin (Barc) 126:321-324.
15. Oh I, Ozaki K, Sato K, Meguro A, Tatara R, Hatanaka K, Nagai T, Muroi K, Ozawa K. 2007. Interferon-gamma and NF-kappaB mediate nitric oxide production by mesenchymal stromal cells. Biochem Biophys Res Commun 355:956-962.
16. Pellicano R, Bonardi R, Smedile A, Saracco G, Ponzetto A, Lagget M, Morgando A, Balzola F, Bruno M, Marzano A, Ponti V, Debernardi Venon W, Ciancio A, Rizzetto M, Astegiano M. 2007. Gastroenterology outpatient clinic of the Molinette Hospital (Turin, Italy): The 2003-2006 report. Minerva Med 98:19-23.
17. R Development Core Team. 2005. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. ISBN 3-900051-07-0, URL http://www.R-project.org.
18. Romero-Gòmez M, Del Mar Viloria M, Andrade RJ, Salmeròn J, Diago M, Fernàndez-Rodrìguez CM, Corpas R, Cruz M, Grande L, Vazquez L, Munoz De-Rueda P, Lopez-Serrano P, Gila A, Gutierrez ML, Perez G, Ruiz-Extremera A, Suarez E, Castillo J. 2005. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 128:636-641.
19. Rott KT, Agudelo CA. 2003. Gout. JAMA 289:2857-2860.
20. Schulz S, Schagdarsurengin U, Suss T, Muller-Werdan U, Werdan K, Glaser C. 2004. Relation between the tumor necrosis factor-alpha (TNF-alpha) gene and protein expression, and clinical, biochemical, and genetic markers: Age, body mass index and uric acid are independent predictors for an elevated TNF-alpha plasma level in a complex risk model. Eur Cytokine Netw 15:105-111.
21. Squadrito GL, Cueto R, Splenser AE, Valavanidis A, Zhang H, Uppu RM, Pryor WA. 2000. Reaction of uric acid with peroxynitrite and implications for the mechanism of neuroprotection by uric acid. Arch Biochem Biophys 376:333-337.
22. Stanzial AM, Benoni G, Cuzzolin L, Gabrielli GB, Pasino M, Perfetti P, Corrocher R. 2003. Urinary nitrite/nitrate concentrations and total antioxidant capacity in patients with chronic hepatitis C in therapy with interferon and ribavirin. J Chemother 15:584-590.
23. Szanto P, Grigorescu M, Dumitru I, Serban A. 2006. Steatosis in hepatitis C virus infection. Response to antiviral therapy. J Gastroenterol Liver Dis 15:117-124.
24. Thomas HC, Torok ME, Forton DM, Taylor-Robinson SD. 1999. Possible mechanisms of action and reasons for failure of antiviral therapy in chronic hepatitis C. J Hepatol 31:152-159.
25. Tsukada K, Hasegawa T, Tsutsumi S, Katoh H, Kuwano H, Miyazaki T, Yamamoto Y. 2000. Effect of uric acid on liver injury during hemorrhagic shock. Surgery 127:439-446.
26. Tsunoda S, Kamide K, Minami J, Kawano Y. 2002, Decreases in serum uric acid by amelioration of insulin resistance in overweight hypertensive patients: Effect of a low-energy diet and an insulin-sensitizing agent. Am J Hypertens 15:697-701.
27. Weiland O. 1999. Treatment of naive patients with chronic hepatitis C. J Hepatol 31:168-173.
28. Yaginuma R, Ikejima K, Okumura K, Kon K, Suzuki S, Takei Y, Sato N. 2006. Hepatic steatosis is a predictor of poor response to interferon alpha-2b and ribavirin combination therapy in Japanese patients with chronic hepatitis C. Hepatol Res 35:19-25.